Blockchain Registration Transaction Record

Nutriband's Abuse-Deterrent Fentanyl Patch Targets $800M Market

Nutriband's AVERSA Fentanyl patch uses abuse-deterrent technology to combat opioid misuse. With $200M-$800M market potential and 2026 FDA filing planned, this innovation addresses the opioid crisis.

This development represents a crucial advancement in addressing the ongoing opioid crisis that has devastated communities nationwide. The AVERSA technology could fundamentally change how potent medications are delivered and monitored, potentially saving countless lives from accidental overdoses and intentional misuse. For patients who genuinely need fentanyl for chronic pain management, this technology ensures they receive proper treatment while minimizing the risk of diversion and abuse. The potential FDA mandate for abuse-deterrent patches across the category could transform pharmaceutical safety standards, creating new regulatory benchmarks for drug delivery systems. This innovation matters because it directly confronts one of the most pressing public health challenges of our time, offering a practical solution that balances effective pain management with critical safety measures.